摘要:
4-Hydroxy-2-methyl-3-(2-pyridylcarbamoyl)-6-trifluoromethyl-2H-thieno[2,3-e]-1,2-thiazine 1,1-dioxide of the formula ##STR1## and its pharmaceutically acceptable salts which possess valuable pharmacodynamic properties are described. More particularly, the compound and its salts display antiinflammatory, analgesic and antirheumatic activities and they are readily accessible by reacting a corresponding alkyl ester with 2-aminopyridine and, if desired, subsequent salt formation.
摘要:
Thienothiazine derivatives of the formula ##STR1## wherein R.sub.1 is lower alkyl; R.sub.2 is an unsubstituted aromatic heterocyclic radical which contains from 1 to 4 hetero atoms or one which is substituted by one or two lower alkyl groups, or is an unsubstituted phenyl radical or one substituted by halogen, hydroxy, lower alkyl, nitro, trifluoromethyl or lower alkoxy; and R.sub.3 and R.sub.4, independently, are hydrogen or lower alkyl,prepared inter alia, from novel intermediates, are described. The end products are useful as anti-inflammatory, analgesic and anti-rheumatic agents.
摘要翻译:式I的噻吩并噻嗪衍生物,其中R 1是低级烷基; R2是未取代的芳族杂环基,其含有1至4个杂原子或被一个或两个低级烷基取代的芳族杂环基,或是未被取代的苯基或被卤素,羟基,低级烷基,硝基,三氟甲基或低级 烷氧基 R 3和R 4独立地是氢或低级烷基,特别是由新的中间体制备。 最终产品可用作抗炎,镇痛和抗风湿药。
摘要:
The present invention relates to compounds of the formula ##STR1## wherein A together with the two carbon atoms to which it is attached forms the group ##STR2## AND THE BROKEN LINE REPRESENTS THE DOUBLE BOND IN GROUP (A); R.sub.1 represents a lower alkyl group; R.sub.2 represents the residue of an aromatic heterocyclic ring containing from 1 to 4 hetero atoms, which may be substituted by one or two lower alkyl groups, or a phenyl group which may be substituted by halogen, hydroxy, lower alkyl, trifluoromethyl or lower alkoxy and R.sub.3 and R.sub.4 each represent a hydrogen atom or a lower alkyl group.Also provided are methods for their preparation. The thienothiazine derivatives provided by this invention have anti-flammatory, analgesic and antirheumatic activity.
摘要:
The invention relates to the use of lornoxicam or analogues thereof which inhibit cyclo-oxygenase 1 and cyclo-oxygenase 2 (COX 1 and COX 2), cannot penetrate the blood-brain barrier under physiological conditions, and reduce the prostaglandin E2-induced induction of the amyloid-precursor-protein (APP), for producing a pharmaceutical composition for the treatment or prevention of Alzheimer's disease or arteriosclerosis.
摘要:
Methods of treating and/or preventing arteriosclerosis are disclosed. In certain methods, a composition containing at least one lornoxicam or lornoxicam analogue that inhibits cyclooxygenase 1 and cyclooxygenase 2 (COX 1 and COX 2), cannot cross the blood/brain barrier under physiological conditions, and reduces the prostaglandin E2-induced induction of the amyloid precursor protein (APP) is administered to a subject to treat and/or prevent arteriosclerosis in the subject.
摘要:
A monoclinic zirconium dioxide with an SiO.sub.2 content below 1.0% by weight is provided which is characterized by dendrite-shaped particles with an average grain size (d.sub.50 value) in a range of 0.5 .mu.m to 3.0 .mu.m and a specific surface (BET) in a range of 3 to 15 m.sup.2 /g. This zirconium dioxide is produced by thermally splitting zirconium silicate in a high-frequency- or medium-frequency induction melting furnace with sintering crust crucible, quenching the melt by blowing on a stream of melt with air and/or spraying it with water and leaching out the thermally split zirconium silicate with concentrated alkali lye at 100.degree. 200.degree. C. The zirconium dioxide of the invention provides a material with improved suitability for the production of zirconium silicate pigments of the host lattice type and inclusion type so as to provide for more color-intensive pigments.
摘要:
Thienyloxyalkylamine derivatives of the general formula: ##STR1## wherein --O--CH.sub.2 --CH.sub.2 --NR.sub.2 R.sub.3 is in position 4 or 5 of the thiophene ring;R.sub.1 is hydrogen, halogen, CF.sub.3, alkyl or alkoxy;R.sub.2 and R.sub.3 are the same or different and are each alkyl, cycloalkyl, alkenyl or alkynyl each having up to 8 C atoms, or NR.sub.2 R.sub.3 is a 5 to 7-membered saturated heterocyclic ring optionally containing a further hetero atom which is oxygen or nitrogen optionally substituted by an alkyl group having 1 to 3 C atoms; andn is an integer of 1 to 5; as well as their acid addition salts, are suitable for treatment of heart rhythm disturbances.
摘要:
Sulphamoylathiophenes of the formula ##STR1## in which Y denotes O or S,A denotes a single bond or a straight-chain or branched alkylene group having 1-5 carbon atoms,R.sub.1 denotes methyl or trifluoromethyl andR.sub.2 denotes hydrogen or a group COOH or COOR.sub.3, in whichR.sub.3 represents (C.sub.1 -C.sub.4)-alkyl,and, in the case in which R.sub.2 denotes a group COOH, their pharmaceutically tolerable salts, a process for their preparation, pharmaceutical preparations which contain these compounds and their use in medicaments as leukotriene antagonists for the treatment of asthma and allergies.
摘要:
Substituted isoxazoles of the formula ##STR1## in which R.sub.1 denotes C.sub.1 -C.sub.4 alkyl, R.sub.2 denotes hydrogen, C.sub.1 -C.sub.4 alkyl chlorine or bromine, R.sub.3 and R.sub.4, which are the same or different are hydrogen or C.sub.1 -C.sub.4 alkyl, but not both hydrogen and n denotes the interger 6, 7, or 8. The novel ocmpounds have a pronounced antiviral action and can be employed for the treatment and prophylaxis of virus diseases.
摘要:
The invention relates to novel derivatives of 4,5-dihydrooxazoles of the formula ##STR1## in which A denotes --CH.dbd.CH-- or --S--,R.sub.1, R.sub.3 and R.sub.4, independently of one another, denote hydrogen or lower alkyl,R.sub.2 denotes hydrogen or lower alkoxy, andn denotes 0 or 1, a process for their preparation, and pharmaceutical preparations which contain these compounds. The novel compounds cause blockage of H.sup.+ /K.sup.+ ATPase and can be used as active ingredients in medicaments for treatment and prophylaxis of disorders which are caused by increased gastric secretions.
摘要翻译:本发明涉及式(I)的4,5-二氢恶唑的新衍生物,其中A表示-CH = CH-或-S-,R1,R3和R4彼此独立地表示氢或低级烷基, R2表示氢或低级烷氧基,n表示0或1,其制备方法和含有这些化合物的药物制剂。 该新化合物引起H + / K + ATP酶的阻断,可用作药物中的活性成分,用于治疗和预防胃分泌物增多引起的疾病。